Welcome to our dedicated page for Elutia news (Ticker: ELUT), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Elutia Inc. develops and commercializes drug-eluting biomatrix products designed to improve compatibility between implanted medical devices and patients. Company news commonly covers financial results, product revenue from SimpliDerm and cardiovascular products, and development updates for NXT-41 and NXT-41x biomatrix technologies used in surgical reconstruction and related applications.
Recurring updates also include regulatory-process disclosures, commercial planning for plastic and reconstructive surgery, management presentations, equity compensation actions, and Nasdaq listing-compliance matters for Elutia's Class A common stock. The company's communications often connect its biomatrix platform with implant-based breast reconstruction, post-surgical infection reduction, and broader surgical-support use cases.
Elutia (Nasdaq: ELUT) granted inducement equity awards on May 13, 2026, under its 2026 Inducement Award Plan to one new employee, consistent with Nasdaq Listing Rule 5635(c)(4).
The grant consists of 48,000 non-qualified stock options at an exercise price of $1.05 per share, with four-year time-based vesting.
Elutia (Nasdaq: ELUT) reported Q1 2026 results and operational progress. Net sales from continuing operations were $3.1 million, up 6% year over year, with GAAP gross margin of 57.9% and adjusted gross margin of 66.5%. Net loss from continuing operations was $7.9 million.
Cash and escrowed funds totaled $36.5 million. FDA review of NXT-41 is advancing, with anticipated 510(k) clearance in Q4 2026 and NXT-41x in the first half of 2027. A new automated manufacturing platform is expected to support gross margins above 80% for NXT-41x. Strategic processes for SimpliDerm and the Cardiovascular line are ongoing.
Elutia (Nasdaq: ELUT) announced that CEO Dr. Randy Mills and CFO Matt Ferguson will present at the 16th Annual LD Micro Invitational on May 18, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles.
Management will discuss Elutia’s drug-eluting biomatrix technology for implant-based breast reconstruction and its role in addressing post-surgical infection, a leading cause of complications and revision surgeries. The presentation begins at 11:30 a.m. Pacific Time and will be available via live webcast. Elutia will also host one-on-one investor meetings on May 18, 2026.
Elutia (Nasdaq: ELUT) will report first quarter 2026 financial results after market close on Thursday, May 14, 2026. Management will host a live conference call and webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT. Registration is required for dial-in and PIN.
A live and archived webcast will be available in the Investors section at http://investors.elutia.com/.
Elutia (Nasdaq: ELUT) will present at the Sidoti Small-Cap Virtual Investor Conference on March 18–19, 2026. Management will discuss the company’s drug-eluting biomatrix technology aimed at reducing post-surgical infection in implant-based breast reconstruction.
The presentation starts at 2:30 p.m. ET on March 19, 2026; registration and one-on-one investor meetings are available via Sidoti’s event site.
Elutia (Nasdaq: ELUT) announced inducement equity awards granted March 10, 2026 to three new employees under its 2026 Inducement Award Plan.
An aggregate of 460,000 non-qualified stock options were granted with a $1.09 exercise price (closing price on March 10, 2026). Options vest 25% after one year, then monthly over three years, subject to continued employment and plan terms.
Elutia (Nasdaq: ELUT) reported fourth-quarter and full-year 2025 results and initiated the regulatory process for its NXT-41 base biologic. The company submitted a 510(k) for NXT-41 and expects FDA clearance in H2 2026, with full NXT-41x drug-eluting clearance anticipated in 1H 2027.
Key financials: $88.0 million BioEnvelope sale closed, transformed balance sheet with $36.4 million cash plus $8.0 million escrowed proceeds, and full repayment of a $26.9 million loan facility.
Elutia (Nasdaq: ELUT) announced on March 4, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price) and Rule 5550(b)(2) (minimum market value of listed securities).
Nasdaq advised the company is now in full compliance with continued listing requirements and that these matters are closed, and Elutia’s Class A common stock will remain listed and traded on the Nasdaq Capital Market under the symbol ELUT.
Elutia (Nasdaq: ELUT) named Pete Ligotti Chief Commercial Officer to lead commercialization of NXT-41x, a next-generation antibiotic-eluting biomatrix targeting post-mastectomy reconstruction. The company cites a ~$1.5B U.S. breast reconstruction market, ~162,000 annual procedures, >80% biologic mesh usage, and persistent infection rates of 15–20%. Elutia is preparing for anticipated FDA clearance in 2027 and will focus on market penetration and reimbursement strategy ahead of launch.
Elutia (NASDAQ: ELUT) will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Management will host a conference call and webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT.
A live and archived webcast will be available in the Investors section at http://investors.elutia.com/. Registered participants receive dial-in details and a PIN, and the system can dial out when the call begins.